| Market Closed - Nasdaq Other stock markets | 5-day change | 1st Jan Change | ||
| 19.63 USD | -1.55% |  | -10.89% | -12.79% |
| May. 17 | HC Wainwright Adjusts Price Target on Cassava Sciences to $131 From $124, Maintains Buy Rating | MT |
| May. 10 | Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 100M | Capitalization | 942M |
|---|---|---|---|---|---|
| Net income 2024 * | -37M | Net income 2025 * | 17M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 9.42x |
| P/E ratio 2024 * | -25.2x | P/E ratio 2025 * | 54.5x | Employees | 29 |
| Yield 2024 * | - | Yield 2025 * | - | Free-Float | 93.4% |
More Fundamentals * Assessed data
Chart Cassava Sciences, Inc.
Dynamic Chart
Latest news about Cassava Sciences, Inc.
| HC Wainwright Adjusts Price Target on Cassava Sciences to $131 From $124, Maintains Buy Rating | MT | |
| Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI | |
| Cassava Sciences Raises More Than $125 Million From Warrant Distribution | MT | |
| North American Morning Briefing : Stock Futures -2- | DJ | |
| North American Morning Briefing : Investors Brace -2- | DJ | |
| Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam | MT | |
| Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials | CI | |
| Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI | |
| Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI | |
| Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer?s Disease Dementia | CI | |
| Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2000 Index | CI | |
| Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000 Index | CI | |
| Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Index | CI | |
| Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell Small Cap Completeness Index | CI | |
| Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell Small Cap Comp Growth Index | CI |
More news
Analyst Recommendations on Cassava Sciences, Inc.
| HC Wainwright Adjusts Price Target on Cassava Sciences to $131 From $124, Maintains Buy Rating | MT | |
| North American Morning Briefing : Stock Futures -2- | DJ | |
| B. Riley Cuts Cassava Sciences' PT to $28 From $44 on 'Uninterpretable' Open-Label Results of Simuflam in Alzheimer's Disease Patients; Keeps Neutral Rating | MT | |
| B. Riley Downgrades Cassava Sciences to Neutral From Buy, Notes Challenging Near-Term Catalyst Profile, Prolonged Litigation Mess; Maintains $44 PT | MT | |
| B. Riley Securities Lowers Cassava Sciences' Price Target to $44 from $58, Retains Buy Rating | MT |
More recommendations
Press releases Cassava Sciences, Inc.
| Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam | AQ | |
| Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam | GL | |
| Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution | GL | |
| Cassava Sciences : Warrants – Notice of Guaranteed Delivery | PU | |
| Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ | GL |
More press releases
News in other languages on Cassava Sciences, Inc.
| MORNING BRIEFING - USA/Asien |
More news
Quotes and Performance
| 1 day | -1.55% | ||
| 1 week | -10.89% | ||
| Current month | -10.89% | ||
| 1 month | -7.01% | ||
| 3 months | +4.53% | ||
| 6 months | -19.52% | ||
| Current year | -12.79% |
More quotes
Highs and lows
1 week
19.42
22.10
1 month
19.42
24.12
Current year
18.18
27.37
1 year
12.32
32.10
3 years
12.32
146.16
5 years
1.03
146.16
10 years
0.76
146.16
More quotes
Managers and Directors - Cassava Sciences, Inc.
| Managers | Title | Age | Since |
|---|---|---|---|
Remi Barbier CEO | Chief Executive Officer | 64 | 98-04-30 |
Eric Schoen DFI | Director of Finance/CFO | 55 | 18-09-30 |
James Kupiec CTO | Chief Tech/Sci/R&D Officer | - | 21-01-03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Remi Barbier CEO | Chief Executive Officer | 64 | 98-04-30 |
Robert Gussin BRD | Director/Board Member | 86 | 03-02-28 |
Patrick Scannon BRD | Director/Board Member | 76 | 07-12-06 |
More insiders
ETFs positioned on Cassava Sciences, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
ADAPTIVE GROWTH OPPORTUNITIES ETF - USD | 0.08% | 248 M€ | +11.05% | - |
ARMOR US EQUITY INDEX ETF - USD | 0.01% | 9 M€ | -.--% | - |
More ETFs positioned on Cassava Sciences, Inc.
Quotes
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 19.63 | -1.55% | 775,736 |
| 24-06-06 | 19.94 | -3.58% | 881,758 |
| 24-06-05 | 20.68 | -1.71% | 702,157 |
| 24-06-04 | 21.04 | -4.36% | 1,198,080 |
| 24-06-03 | 22 | -0.14% | 367,841 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
Company Profile
Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.
Sector
Calendar
2024-07-30 - Q2 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company
Income Statement Evolution
More financial data
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
19.63USD
Average target price
103USD
Spread / Average Target
+424.71%
Consensus
EPS Revisions
Estimates Revisions
Quarterly earnings - Rate of surprise
Company calendar
Sector Bio Therapeutic Drugs
| 1st Jan change | Capi. | |
|---|---|---|
CASSAVA SCIENCES, INC. | -12.79% | 942M |
VERTEX PHARMACEUTICALS INCORPORATED | +18.72% | 125B |
REGENERON PHARMACEUTICALS, INC. | +14.19% | 108B |
BIONTECH SE | -4.93% | 24.21B |
ARGENX SE | +3.23% | 22.78B |
GENMAB A/S | -10.44% | 17.96B |
WUXI APPTEC CO., LTD. | -41.74% | 16.43B |
BEIGENE, LTD. | -13.31% | 16.37B |
NEUROCRINE BIOSCIENCES, INC. | +2.44% | 13.58B |
SAREPTA THERAPEUTICS, INC. | +27.89% | 11.66B |
Bio Therapeutic Drugs
- Stock Market
- Equities
- SAVA Stock
